// App-Quantinova.ai

CTP28 2015 ASA : A Phase III Clinical Trial To Evaluate The Reversal Effects Of Idarucizumab On Active Dabigatran (RE-VERSE AD)

Researchers

Presenter

  • R Dubiel

Principal Investigators

  • John Eikelboom

  • S Wang

  • J Weitz

  • R Bernstein

  • Menno Huisman

  • Elaine Hylek

  • C W Kam

  • P Kamphuisen

  • Jorg Kreuzer

  • J Levy

  • Paul Reilly

  • B Wang

Medical Centers

  • Northwestern University, Chicago, IL

  • McMaster University, Hamilton, ON, Canada

  • Boston Univ., Boston, MA.

  • Medical Center Groningen, Groningen, Netherlands

  • Queen Mary Hospital, Hong Kong, Hong Kong

  • Duke Hosp, Durham, NC

  • Leiden University, Leiden, Netherlands

  • University of Pennsylvania, Philadelphia, PA

Locations

  • United States

  • Canada

  • Hong Kong

  • Netherlands

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pradax

  • Idarucizumab

Outcome

  • N/A

Study Design

  • open label

  • pharmacokinetics

  • single arm

Phase

  • NA

Study Id's

  • NCT02104947

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved